Roche Sales Drop 5 Percent Amid Currency Headwinds
The Swiss drugmaker reported quarterly revenue of 14.7 billion francs as a strong franc weighed on international sales. Growth in key drugs helped shares rise.
Xurve View
Insights:
Xurve View
ROCHE HOLDING AG-BR reported a 5% decline in first-quarter sales on Thursday, as significant currency headwinds overshadowed a robust underlying performance in its core pharmaceuticals business. The Switzerland based healthcare giant posted group revenue of 14.7 billion Swiss francs ($18.7 billion), meeting analyst expectations despite the impact of a strengthening Swiss franc against the United States dollar.
